Acesso livre
Acesso livre

Covid-19: qual é a evidência para o uso do antiviral Paxlovid?

29 Abr, 2022 | 15:16h

Covid-19: What is the evidence for the antiviral Paxlovid? – The BMJ

Conteúdos relacionados:

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator – World Health Organization

A living WHO guideline on drugs for covid-19 – The BMJ

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions – Annals of Internal Medicine

The COVID-19 Treatment Guidelines Panel’s Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications – NIH COVID-19 Treatment Guidelines Panel


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.